🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against increasingly resistant strains of the pathogen, according to scientists.

An International Challenge

Cases of gonorrhoea are increasing around the world, with figures suggesting more than 82 million new cases annually. Particularly high rates are seen in the African continent and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely advancement in the context of rising global incidence, escalating drug resistance and the very limited therapeutic options currently available.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has designated it as a "high-priority threat". Ongoing monitoring revealed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Receive Clearance

Zoliflodacin, marketed under the name a brand name, was approved by the US FDA in recent days for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts hope that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in concurrent days. This medication, which is employed against urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to see it through.

“This authorization represents a significant shift in the treatment of superbug gonorrhoea, which until now has been evolving faster than antibiotic development.”

Clinical Trial Results and Global Access

Based on findings released by a major medical journal, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the typical regimen, which combines two antibiotics. The research enrolled nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the ability to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians directly involved have voiced positive views. The availability of a single-dose, oral treatment such as this is seen as a "game-changer" for managing the epidemic. This is viewed as vital to alleviate the strain of the infection for patients and to prevent the spread of extremely resistant gonorrhoea worldwide.